Literature DB >> 33575212

Systematic Construction and Validation of an RNA-Binding Protein-Associated Model for Prognosis Prediction in Hepatocellular Carcinoma.

Siyuan Tian1, Jingyi Liu2, Keshuai Sun1, Yansheng Liu1, Jiahao Yu1, Shuoyi Ma1, Miao Zhang1, Gui Jia1, Xia Zhou1, Yulong Shang1, Ying Han1.   

Abstract

BACKGROUND: Evidence from prevailing studies show that hepatocellular carcinoma (HCC) is among the top cancers with high mortality globally. Gene regulation at post-transcriptional level orchestrated by RNA-binding proteins (RBPs) is an important mechanism that modifies various biological behaviors of HCC. Currently, it is not fully understood how RBPs affects the prognosis of HCC. In this study, we aimed to construct and validate an RBP-related model to predict the prognosis of HCC patients.
METHODS: Differently expressed RBPs were identified in HCC patients based on the GSE54236 dataset from the Gene Expression Omnibus (GEO) database. Integrative bioinformatics analyses were performed to select hub genes. Gene expression patterns were validated in The Cancer Genome Atlas (TCGA) database, after which univariate and multivariate Cox regression analyses, as well as Kaplan-Meier analysis were performed to develop a prognostic model. Then, the performance of the prognostic model was assessed using receiver operating characteristic (ROC) curves and clinicopathological correlation analysis. Moreover, data from the International Cancer Genome Consortium (ICGC) database were used for external validation. Finally, a nomogram combining clinicopathological parameters and prognostic model was established for the individual prediction of survival probability.
RESULTS: The prognostic risk model was finally constructed based on two RBPs (BOP1 and EZH2), facilitating risk-stratification of HCC patients. Survival was markedly higher in the low-risk group relative to the high-risk group. Moreover, higher risk score was associated with advanced pathological grade and late clinical stage. Besides, the risk score was found to be an independent prognosis factor based on multivariate analysis. Nomogram including the risk score and clinical stage proved to perform better in predicting patient prognosis.
CONCLUSIONS: The RBP-related prognostic model established in this study may function as a prognostic indicator for HCC, which could provide evidence for clinical decision making.
Copyright © 2021 Tian, Liu, Sun, Liu, Yu, Ma, Zhang, Jia, Zhou, Shang and Han.

Entities:  

Keywords:  RNA-binding proteins; The Cancer Genome Atlas (TCGA); hepatocellular carcinoma; prognostic model; survival analysis

Year:  2021        PMID: 33575212      PMCID: PMC7870868          DOI: 10.3389/fonc.2020.597996

Source DB:  PubMed          Journal:  Front Oncol        ISSN: 2234-943X            Impact factor:   6.244


  42 in total

1.  NetworkAnalyst for statistical, visual and network-based meta-analysis of gene expression data.

Authors:  Jianguo Xia; Erin E Gill; Robert E W Hancock
Journal:  Nat Protoc       Date:  2015-05-07       Impact factor: 13.491

2.  Isolation of growth suppressors from a cDNA expression library.

Authors:  D G Pestov; T M Grzeszkiewicz; L F Lau
Journal:  Oncogene       Date:  1998-12-17       Impact factor: 9.867

Review 3.  A census of human RNA-binding proteins.

Authors:  Stefanie Gerstberger; Markus Hafner; Thomas Tuschl
Journal:  Nat Rev Genet       Date:  2014-11-04       Impact factor: 53.242

4.  RNA-binding motif protein 43 (RBM43) suppresses hepatocellular carcinoma progression through modulation of cyclin B1 expression.

Authors:  Huan Feng; Juan Liu; Yangyang Qiu; Yao Liu; Hexig Saiyin; Xiao Liang; Fen Zheng; Ying Wang; Deke Jiang; Ying Wang; Long Yu; Wei Su; Suqin Shen; Jiaxue Wu
Journal:  Oncogene       Date:  2020-07-06       Impact factor: 9.867

5.  The polycomb group protein EZH2 is involved in progression of prostate cancer.

Authors:  Sooryanarayana Varambally; Saravana M Dhanasekaran; Ming Zhou; Terrence R Barrette; Chandan Kumar-Sinha; Martin G Sanda; Debashis Ghosh; Kenneth J Pienta; Richard G A B Sewalt; Arie P Otte; Mark A Rubin; Arul M Chinnaiyan
Journal:  Nature       Date:  2002-10-10       Impact factor: 49.962

6.  Splicing Regulator p54nrb /Non-POU Domain-Containing Octamer-Binding Protein Enhances Carcinogenesis Through Oncogenic Isoform Switch of MYC Box-Dependent Interacting Protein 1 in Hepatocellular Carcinoma.

Authors:  Zhixiang Hu; Liangqing Dong; Shengli Li; Zhe Li; Yejun Qiao; Yuchen Li; Jie Ding; Zhiao Chen; Yangjun Wu; Zhen Wang; Shenglin Huang; Qiang Gao; Yingjun Zhao; Xianghuo He
Journal:  Hepatology       Date:  2020-03-25       Impact factor: 17.425

Review 7.  Liver cancer: descriptive epidemiology and risk factors other than HBV and HCV infection.

Authors:  Shu-Chun Chuang; Carlo La Vecchia; Paolo Boffetta
Journal:  Cancer Lett       Date:  2008-12-16       Impact factor: 8.679

8.  Inhibitors of enhancer of zeste homolog 2 (EZH2) activate tumor-suppressor microRNAs in human cancer cells.

Authors:  S Hibino; Y Saito; T Muramatsu; A Otani; Y Kasai; M Kimura; H Saito
Journal:  Oncogenesis       Date:  2014-05-26       Impact factor: 7.485

9.  HuR/ELAVL1 drives malignant peripheral nerve sheath tumor growth and metastasis.

Authors:  Marta Palomo-Irigoyen; Encarni Pérez-Andrés; Marta Iruarrizaga-Lejarreta; Adrián Barreira-Manrique; Miguel Tamayo-Caro; Laura Vila-Vecilla; Leire Moreno-Cugnon; Nagore Beitia; Daniela Medrano; David Fernández-Ramos; Juan José Lozano; Satoshi Okawa; José L Lavín; Natalia Martín-Martín; James D Sutherland; Virginia Guitiérez de Juan; Monika Gonzalez-Lopez; Nuria Macías-Cámara; David Mosén-Ansorena; Liyam Laraba; C Oliver Hanemann; Emanuela Ercolano; David B Parkinson; Christopher W Schultz; Marcos J Araúzo-Bravo; Alex M Ascensión; Daniela Gerovska; Haizea Iribar; Ander Izeta; Peter Pytel; Philipp Krastel; Alessandro Provenzani; Pierfausto Seneci; Ruben D Carrasco; Antonio Del Sol; María Luz Martinez-Chantar; Rosa Barrio; Eduard Serra; Conxi Lazaro; Adrienne M Flanagan; Myriam Gorospe; Nancy Ratner; Ana M Aransay; Arkaitz Carracedo; Marta Varela-Rey; Ashwin Woodhoo
Journal:  J Clin Invest       Date:  2020-07-01       Impact factor: 14.808

10.  EZH2 negatively regulates PD-L1 expression in hepatocellular carcinoma.

Authors:  Gang Xiao; Li-Lian Jin; Chao-Qun Liu; Yong-Chun Wang; Ya-Ming Meng; Zhong-Guo Zhou; Jing Chen; Xing-Juan Yu; Yao-Jun Zhang; Jing Xu; Limin Zheng
Journal:  J Immunother Cancer       Date:  2019-11-14       Impact factor: 13.751

View more
  3 in total

Review 1.  Impact of Alternative Splicing Variants on Liver Cancer Biology.

Authors:  Jose J G Marin; Maria Reviejo; Meraris Soto; Elisa Lozano; Maitane Asensio; Sara Ortiz-Rivero; Carmen Berasain; Matias A Avila; Elisa Herraez
Journal:  Cancers (Basel)       Date:  2021-12-21       Impact factor: 6.639

2.  A novel machine learning derived RNA-binding protein gene-based score system predicts prognosis of hepatocellular carcinoma patients.

Authors:  Qiangnu Zhang; Yusen Zhang; Yusheng Guo; Honggui Tang; Mingyue Li; Liping Liu
Journal:  PeerJ       Date:  2021-12-20       Impact factor: 2.984

3.  Construction and validation of a prognostic model with RNA binding protein-related mRNAs for the HBV-related hepatocellular carcinoma patients.

Authors:  Shaohua Xu; Hui Liu; Renyun Tian; Jiahui Xie; Su Chen; Junyun Luo; Haizhen Zhu; Yirong Wang; Zhaoyong Li
Journal:  Front Oncol       Date:  2022-09-23       Impact factor: 5.738

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.